|
🇨🇳 China Funding Weekly
Issue #001 · 25 Feb – 4 Mar 2026
|
March 4, 2026
|
|
|
This Week in China Funding
11 rounds tracked this week · $1.8B total disclosed. Active sectors: ai, hardware, healthtech.
AI dominated Chinese startup funding this week in both volume and capital weight, with Galaxea AI's $1.45B Series B alone accounting for the overwhelming majority of disclosed capital—a signal that Chinese investors are making concentrated, high-conviction bets on embodied and enterprise AI rather than spreading exposure across the sector. Geographic data is thin this week, but the handful of tagged locations (Shanghai, Shenzhen, Suzhou) suggest activity is distributed across the usual tier-one hubs rather than consolidating around a single city. Round structure is distinctly bifurcated: a small number of massive growth-stage rounds are absorbing nearly all disclosed capital, while the majority of deals are early-stage angel and seed rounds with undisclosed amounts, pointing to a healthy but cautious pre-institutional pipeline. The pattern worth watching is the pairing of large AI rounds with early robotics activity (PERCISPHERE at Series A, Qingyu at angel)—this mirrors a broader Chinese investment thesis that AI and physical automation are converging, and European investors should expect cross-sector AI-robotics deals to become a recurring feature rather than an outlier.
|
|
Top Rounds This Week
|
Galaxea AI
星海图
Series B
ai
|
$1.4B
|
The staggering scale of this raise—over $1.4 billion at Series B—points to a Chinese market where humanoid robotics and embodied AI are attracting sovereign-scale capital well before the technology reaches commercial maturity, compressing a timeline that Western markets are treating as a decade-long build. European founders working in industrial automation, robotics software, or edge AI should note that Chinese competitors are now being resourced at a level that will accelerate hardware-software integration and drive down unit economics faster than most Western roadmaps anticipate.
Read source →
|
|
The sheer scale of a $217M Series B in an undisclosed sector points to Chinese investors doubling down on a company with clear traction, likely in AI, robotics, or industrial automation — the verticals currently attracting outsized late-stage bets in China. European founders should watch for what Linkerbot reveals about its core product, as Chinese B2B platforms at this funding level often signal category-defining plays that will eventually pressure Western incumbents or spawn copycat opportunities.
Read source →
|
|
China's continued flow of strategic capital into AI-powered consumer hardware signals that the augmented reality wearables race is accelerating well beyond the Meta-Apple duopoly narrative dominating Western headlines. European startups building spatial computing applications or XR peripherals should watch XREAL's distribution partnerships closely, as Chinese hardware players are increasingly using these rounds to fund aggressive European market entry rather than domestic consolidation.
Read source →
|
|
Rona Therapeutics
Series A
biotech
|
$33M
|
A $33M Series A flowing into Chinese RNA therapeutics signals that domestic capital is doubling down on nucleic acid medicine as a strategic alternative to Western biotech pipelines, particularly as geopolitical tensions constrain cross-border drug licensing. European RNA-focused startups and biotech investors should watch whether Rona's advances in siRNA or antisense platforms create both competitive pressure and potential out-licensing opportunities in markets where Chinese firms are still seeking regulatory credibility.
Read source →
|
|
Atome
Strategic
fintech
|
$31M
|
Buy-now-pay-later infrastructure is attracting renewed capital in China despite broader fintech regulatory headwinds, signaling that embedded consumer credit — when backed by a well-capitalized parent — remains a defensible growth lever in Asia's retail ecosystem. European BNPL players eyeing Southeast Asian expansion should note that Atome's parent-led round reflects a consolidation dynamic where only vertically integrated or platform-backed operators are surviving the tighter compliance environment, raising the bar for independent entrants.
Investors:
parent firm
Read source →
|
|
|
All Rounds This Week
|
|
|
|